AllDocs -> cancers

ANY ALTERATION TO THIS STATEMENT WILL INVALIDATE THIS ENTRY If you sign this entry form on behalf of another person you are acting as agent on behalf of the owner or that person and YOU TAKE FULL RESPONSIBILITY for the consequences of the statement that you are signing. Please print your name alongside your own signature if signing on behalf of someone else. PLEASE NOTE THAT ENTRIES ARE NOT TRANSFERABLE AND CAN ONLY BE USED BY THE PERSON AND EXHIBIT HEREBY ENTERED. ALL EXHIBITS ACCEPTED AT THE DISCRETION OF THE ORGANISERS I hereby certify this exhibit will be covered by public Liability Insurance or a current Motor Insurance policy and that the property is exhibited at the owners risk. The Policy or Certificate of Insurance will be available for production on the day of the rally if required. Signed Date .. A cheque payable to LEUKAEMIA RESEARCH FUND for £ .. is enclosed. PLEASE RETURN THE COMPLETED ...

Leukaemia Introduction Leukaemias are a group of cancers which can occur in people of any age. Leukaemias are disorders of blood cell production that result in the body accumulating abnormal blood cells. Normally the body's cells are replaced by dividing in an orderly way, allowing your body to grow and to heal after an injury. Sometimes some cells act in an abnormal way and may grow into a lump which is called a tumour. Tumours can be benign (not a cancer) or malignant (a cancer). Malignant tumours can spread to other parts of the body forming secondary cancer deposits in other areas of the body. In leukaemia it is the blood-forming cells which multiply abnormally and grow out of control. Even though leukaemias may not produce lumps they are still a type of cancer. These cancers may be either leukaemias or lymphomas . Structure and function of blood and ...

U HB has opened the doors to a new £5 million Leukaemia Centre – the first of its kind in the UK. The centre was officially opened by former England, Wolves and Crystal Palace striker Geoff Thomas, who fought the disease three years ago and who has dedicated himself to raising money for the charity Cure Leukaemia . The Centre, based in the grounds of the Queen Elizabeth Hospital has been funded through a £2.2 million grant from Advantage West Midlands and the Trust, and is set to transform the environment for patients receiving treatment for Leukaemia . Over the last five years, major investment has been spent on clinical and basic research programmes into leukaemia at UHB, making the Trust a national centre of excellence. As a result, the leukaemia and stem cell transplant programmes have doubled in size and are now one of the three largest in the country. ...

Could visible light contribute to the development of leukaemia and other cancers in children? q Thomas C. Erren * Institute and Policlinic for Occupational and Social Medicine, School of Medicine and Dentistry, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Köln, Lindenthal, Germany Received 20 September 2004; accepted 23 September 2004 Summary This paper suggests to rigorously test the hypothesis that there are causal links between visible light and the development of leukaemia and other cancers in children. Light can be considered as a candidate risk factor because it suppresses melatonin biosynthesis which may play a role in a series of anticancer defences. Indeed, melatonin may offer some protection against all ‘‘hallmarks of cancer’’ [i.e., self-sufficiency in growth signals; insensitivity to growth- inhibitory signals; evasion of programmed cell death (apoptosis); ...

Page 2 Mortality trends in England; ICD9 (205), ICD10 (C92); File: Sepho 96-04 V2 Myeloid leukaemia in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for myeloid leukaemia in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

Page 2 Mortality trends in England; ICD9 (204), ICD10 (C91); File: Sepho 96-04 V2 Lymphoid leukaemia in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for lymphoid leukaemia in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

Do electric and magnetic fields cause childhood leukaemia ? A review of the scientific evidence Prepared for CHILDREN with LEUKAEMIA by Dr Adrienne Morgan and Katie Martin BSc Registered Charity No. 298405. Inaugurated in 1988 by Diana, Princess of Wales in memory of Jean and Paul O’Gorman CHILDREN with LEUKAEMIA Fighting Britain’s biggest child killer disease Magnetic fields document 24/5/06 3:59 pm Page 1 Page 2 2 Contents Contents page Executive summary 4 1 Introduction 5 1.1 Electric and Magnetic fields 5 1.1.1 Magnetic fields 6 1.1.2 Electric fields 6 1.2 Childhood leukaemia 6 1.2.1 Types of childhood leukaemia 6 1.2.2 The genetic basis of leukaemia 7 1.2.3 Incidence ...

0335 Progression of multidrug resistance in leukaemia cells is accompanied by distinct changes in subcellular distribution of early and late endocytic organelles Jing Jin, Arwyn T. Jones Welsh School of Pharmacy, Cardiff University, Cardiff Multidrug resistance (MDR) constitutes a major impediment to cancer therapy. Chemotherapeutic drugs are often weak-bases with nuclear targets and distribute through the cyto- and nucleoplasm of drug- sensitive cells but are excluded from the nucleus of MDR cells. Analysis of MDR cells suggest that changes in endocytic pathways, such as decreased lysosomal pH, contribute to sequester weak-base drugs from the nucleus. However little information is available to explain the tle information is available to explain the le information is available to explain the underlying molecular mechanisms. Using a sensitive and MDR variant of leukaemia HL-60 ...

M. Vobis 1 , J. D’Haese 1 , H. Mehlhorn 1 ( ? ), N. Mencke 2 1 Institute for Zoomorphology, Cell Biology and Parasitology, Heinrich-Heine University, 40225 Düsseldorf, Germany 2 Bayer HealthCare AG, Animal Health Division, 51368 Leverkusen, Germany ? e-mail: mehlhorn@uni-duesseldorf.de Parasitol Res (2005) 97:S102–S106 DOI 10.1007/s00436-005-1452-1 Abstract Cat fleas ( Ctenocephalides felis ) were fed via artificial membranes and infected with the feline leukaemia virus (FeLV) from cell cultures. After removing the fleas from the blood source,the quantity of virus in the flea and its faeces was measured over a defined period of time. The virus was detectable in the fleas for up to 30 h at room temperature and up to 115 h at 4°C. In the faeces, the amount of ...

Registered Charity No. 298405. Inaugurated in 1988 by Diana, Princess of Wales in memory of Jean and Paul O’Gorman CHILDREN with LEUKAEMIA Electric and magnetic fields (EMF) are created by the presence of electricity. They surround us in modern life and are produced in varying degrees and strengths by all elements of the electricity supply system – from high voltage power lines to the electrical appliances in our homes. EMF have come under scrutiny as a possible source of harm and have been blamed for a wide range of adverse health effects. A great deal of research has been carried out investigating these possible effects, with mixed results. Perhaps the largest body of evidence relates to childhood leukaemia where there is now the strongest evidence of a link. Epidemiology The bulk of the evidence comes from ...

All Records First Record Next Record Make PDF Universität Zürich > Medizinische Fakultät > Kinderspital Zürich > Onkologie, Abteilung > PD Dr. Felix Niggli Summary / Zusammenfassung Acute lymphoblastic leukaemia (ALL) is the most common childhood malignancy . Treatment stratification is based on various risk factors. Recently it was shown that disappearance of minimal residual disease after the begin of treatment may be one of the strongest predictors for the success of the long term outcome. We therefore would like to combine expertise in detection of minimal residual disease in patients with ALL with recent advances in cDNA-based gene expression profiling. The goal of this project will be to use gene expression profiling at diagnosis to predict subgroups of paediatric ALL patients according to risk categories previously established using PCR-based minimal residual disease detection. ...

Hodgkin’s lymphoma & other lymphomas myeloma • myelodysplasia • aplastic anaemia the myeloproliferative disorders • the leukaemias Revised Sep 2003 Page 2 Acknowledgements The Leukaemia Research Fund gratefully acknowledges the help and advice of many clinicians who have generously given their time to aid in preparation of our patient information publications. A list can be found at www.lrf.org.uk/advisors/ Published by Leukaemia Research Fund , April 2001 43 Great Ormond Street London WC1N 3JJ Tel: 020 7405 0101 Email: info@lrf.org.uk Fax: 020 7242 1488 Web: www.lrf.org.uk Registered Charity 216032 Revised and Reprinted September 2003 © All rights reserved. No part of this publication may be reproduced or transmitted without permission in writing from Leukaemia Research Fund. Series Author: Ken ...

abc H o d g k i n ’s disease & other lymphomas myeloma • myelodysplasia • aplastic anaemia the myeloproliferative disorders • the leukaemias Page 2 Acknowledgements Leukaemia Research Fund gratefully acknowledges the help and advice of Professor A. V. Hoffbrand in reviewing this series of publications and the assistance of Professor A. Burnett, Professor D. Catovsky, Professor J. Chessells, Professor J. Goldman, Dr A. Haynes, Professor G. Morg a n , Dr S. O’Brien, and Professor J. Sweetenham in the preparation of specific titles. Published by Leukaemia Research Fund , April 2001 43 Great Ormond Street L o n d o n WC1N 3JJ Tel: 020 7405 0101 Email: info@lrf.org . u k Fax: 020 7242 1488 Web: www. l r f . o rg . u k Registered Charity 216032 © All rights reserved. No part of this publication may be reproduced or transmitted ...

European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40 E-mail: orphandrugs@emea.eu.int www.emea.eu.int EMEA 2006 Reproduction and/or distribution of this document is authorised for non-commercial purposes only provided the EMEA is acknowledged Document Date: London, 9 June 2006 Doc.Ref.: EMEA/COMP/137639/2006draft COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PUBLIC SUMMARY OF POSITIVE OPINION FOR ORPHAN DESIGNATION OF nilotinib for the treatment of chronic myeloid leukaemia On 22 May 2006, orphan designation (EU/3/06/375) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for nilotinib for the treatment of chronic myeloid leukaemia . What is chronic myeloid leukaemia ? Chronic myeloid leukemia ...

Acute Promyelocytic Leukaemia (APL) Page 2 The booklets in this series are intended to provide general information about the diseases they describe. In many cases the treatment of individual patients will differ from that described in the booklets. At all times patients should rely on the advice of their specialist who is the only person with full information about their diagnosis and medical history. © All rights reserved. No part of this publication may be reproduced or transmitted without permission in writing from Leukaemia Research. Leukaemia Research 43 Great Ormond Street, London, WC1N 3JJ 020 7405 0101 www.lrf.org.uk email: info@lrf.org.uk Registered charity 216032 For further advice contact the clinical information team on 020 7269 9060. Series compiled by Ken Campbell MSc, revised 2006. A list ...

Household insecticides could double child leukaemia risk The Times, January 17, 2006 By Sam Lister, Health Correspondent http://www.timesonline.co.uk/article/0,,13509-1988878,00.html CHILDREN frequently exposed to household insecticides used on plants, lawns and in head lice shampoos appear to run double the risk of developing childhood leukaemia , research suggests. A study by French doctors, published today in the journal Occupational and Environmental Medicine , supports concerns raised in recent years about the use of toxic insecticides around the home and garden — including plant sprays, medication shampoos and mosquito repellents — and a possible correlation with increased rates of acute leukaemia in children. The latest study by Inserm, France’s national institute for medical research, was based on 280 children who had acute leukaemia , newly diagnosed and 288 children matched ...

RaceAhead Event Timing Cure Leukaemia - 5K - Result Asics Cure Leukaemia 5k Race Race# Forename Surname Gender Position Gun Time Chip Time 3036 Jamie Johnston Male 1 00:17:34 00:17:34 3111 Jonathon Antill Male 2 00:19:03 00:18:59 3044 Tim Edwards Male 3 00:19:11 00:19:08 3504 Spare Entry Male 4 00:19:29 00:19:26 3443 Robert Parkes Male 5 00:19:56 00:19:55 3109 David Banks Male 6 00:20:01 00:19:57 3081 Richard Baughan Male 7 00:20:17 00:20:13 3125 Ryan Goodman Male 8 00:20:35 00:20:33 3475 Tony Myers Male 9 00:20:53 00:20:46 3522 Sam Elgar Male 10 ...

RaceAhead Event Timing Asics Cure Leukaemia Run - 10K - Result Race# Forename Surname Gender Position Gun Time Chip Time 307 Ian Mansell Male 1 00:35:08 00:35:06 569 Matt Giles Male 2 00:35:32 00:35:30 573 Beth Eburne Female 3 00:36:07 00:36:05 521 James Picksley Male 4 00:36:15 00:36:13 450 Tom Crosby Male 5 00:36:33 00:36:31 470 Sam Collins Male 6 00:37:08 00:36:57 570 Matt Raden Male 7 00:37:10 00:37:07 480 Matthew Andrews Male 8 00:37:14 00:37:12 336 David Andrew Dale Male 9 00:37:23 00:37:21 581 Pedro Lyons Male 10 ...

RESULTS 1 0:21:37 RICHARDSON, Ben Bromsgrove & Redditch AC JunM 509 1 2 0:21:38 BYNG, James Unattached SenM 536 2 3 0:21:50 DAVIS, Antony Unattached M35+ 553 3 4 0:23:35 JOHNSON, Craig Worcester AC JunM 544 4 5 0:24:46 BYNG, Nicholas Tri-Team/BTA SenM 537 5 6 0:24:51 WOODWISS, Lauren Unattached JunW 810 6 7 0:25:00 RICHARDSON, Philip Bromsgrove & Redditch AC M35+ 510 7 8 0:25:44 HARVEY, Paul Unattached SenM 549 8 9 0:26:10 WATSON, Jake Unattached JunM 517 9 10 0:26:11 PHILLIPS, John Unattached M35+ 518 10 11 0:26:48 WARD, Lucy Unattached SenW 885 11 12 0:27:00 JARNIS, Gary Unattached SenM 524 12 13 ...

RESULTS 1 0:33:07 MALIN, Richard Bromsgrove & Redditch AC M35+ 175 1 2 0:35:59 LEWIS, Mark Royal Navy AC M35+ 99 2 3 0:36:17 KEYTE, Ian Bromsgrove & Redditch AC M35+ 125 3 4 0:36:33 OLINS, Paul Bromsgrove & Redditch AC M35+ 137 4 5 0:36:36 MCGILL, Trevor Droitwich AC M35+ 101 5 6 0:36:42 DANDO, Richard Unattached SenM 169 6 7 0:37:03 DAVIES, Paul Centurion RC M35+ 78 7 8 0:37:14 BURKE, Kevin Stourbridge RC M35+ 102 8 9 0:37:19 PENN, Chris Unattached SenM 39 9 10 0:38:16 JENKINS, Huw Bromsgrove & Redditch AC M35+ 29 10 11 0:38:29 GRAHAM, Mark Bromsgrove & Redditch AC M35+ 106 11 12 0:38:48 ATKINS, Paul Bromsgrove ...

5 Chronic myeloid leukaemia : the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Kay Barnes, Elizabeth McIntosh and Stephen A. Baldwin Introduction In chronic myeloid leukaemia (CML) expression of the chimeric tyrosine kinase, Bcr-Abl, promotes the inappropriate survival of haemopoietic stem cells by a non-autocrine mechanism in the absence of the growth factor, IL-3. Stimulation of glucose uptake appears to play an important role in the suppression of apoptosis by this cytokine in normal haemopoietic cells. To investigate whether the cell survival mechanisms mediated by the oncogene and cytokine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for tetracycline-inducible expression of Bcr-Abl. Role of the glucose transporter, GLUT1, in glucose transport regulation in TonB210 cells Bcr-Abl tyrosine kinase expression in ...

Pakistan falls into a low risk region for Non- Hodgkins Lymphoma (NHL) in males and females, graded 1 on a scale of 1-5. Males and females fall into a moderate risk region for leukaemia , graded 2 for males and 3 for females on the same scale (Figure 1). 1 These estimates are based on the data of Karachi South published in the Cancer Incidence in the Five Continents. 2 Karachi South (KS) is the southern-most district of Karachi with a population of 1,724,915; 929,394 (54%) males and 795,521 (46%) females; annual growth rate of 1.94% as calculated by the Federal Census Bureau. 3 The population distribution of KS is similar to the population distribution of Pakistan as regards age, gender, and religion. KS has the distinction of being the only district in the coun- try with a representation of all ethnic and socio-economic groups of the country. It thus ...

Mortality from Leukaemia Across Bedfordshire and Hertfordshire (SMR) 2002-2004, All Ages, by Primary Care Trust (PCT) Notes Mortality from leukaemia (ICD10 C91-C95) Indirectly standardised ratios (SMR) All ages 2002-04 (Pooled) England 2002-04 = 100 (Standard rates are England annual age-specific rates 2002-04) Data are based on the original underlying cause of death. Data are based on the latest revisions of ONS population estimates for the respective years, current as of the 20th December 2005. Highlights The all persons mortality ratio for leukaemia was significantly lower than England in South East Hertfordshire PCT The highest leukaemia mortality ratio was in Watford & Three Rivers PCT, which was not significantly different to England. For More Information Please Contact David Edwards, Public Health Intelligence Epidemiologist (david.edwards@phi-bedsherts.nhs.uk) ...

* Classified Specialist (Pathology), CH(CC), Lucknow. + Ex-Senior Advisor(Pathology), CH(CC). Lucknow Received : 23.06.2005; Accepted : 23.08.2005 Case Report Introduction A cute leukaemia may present with extremely high blast counts, a phenomenon known as hyperleucocytosis. It is blood blast count greater than 100,000/cmm and occurs occasionally in Acute Myelogenous Leukaemias [1]. The risk of death is disproportionately high (20% to 40%) when acute hyperleucocytosis is present. Respiratory failure, intracranial haemorrhage and severe metabolic abnormalities occur frequently and are the primary determinants of high mortality. Risk of death due to haemorrhage in the central nervous system is higher in acute myeloblastic leukaemia , lymphoblastic leukaemia and blastic phase of chronic mylogenous leukaemia when thrombocytopenia and hyperleucocytosis ...

Adjusted rates 2004 Leukaemia ?91-?95 59 Table 1 General rates, 2004 Incidence: number of new cases 3814 2060 1754 Incidence (crude rate) 8.0 9.4 6.9 Incidence (age-standardised, world standard) 6.2 7.9 5.0 Incidence (age-standardised, Ukrainian standard) 7.8 10.5 6.1 Change of incidence rate 2004 in comparison with 2003 (age-standardized rates, Ukrainian standard, %) 1.30 0.09 3.55 Mortality: number of new cases 2526 1427 1099 Mortality (crude rate) 5.3 6.5 4.3 Mortality (age-standardised, world standard) 3.8 5.2 2.8 Mortality (age-standardised, Ukrainian standard) 5.1 7.4 3.8 Lived less than 1 year since the diagnosis in 2004, % 40.7 40.4 41.0 From among the newly diagnosed – diagnosed ...

© JAPI • VOL. 54 • MAY 2006 www.japi.org 405 Case Report Hyperleukocytosis Associated Pulmonary Leukostasis in Acute Leukaemia H Singh*, BNS Prasad**, Jagdish***, A Batra+ Abstract Leukostasis is a fatal complication in granulocytic leukaemia . Brain and lung are most commonly involved organs in leukostasis. In the lung, the clinical presentation simulates infections and haemorrhagic complications of acute leukaemia . Being a medical emergency, early recognition of leukostasis and initiation of therapy prevents mortality. © essentially normal. Laboratory evaluation revealed normal biochemical parameters especially renal and liver function tests. Complete haemogram showed: Hb - 2gm%; TLC 1,20,000/cmm with 90% blast; and platelets – 60,000/cmm. Bone marrow aspiration showed acute promyelocytic leukaemia (M3). Chest X-ray was normal (Fig. 1). Electrocardiogram ...

1 The genomics of leukaemia Contents Abbreviations 2 Abstract 3 Introduction 3 Incidence and mortality 5 Types of leukaemia 6 Classification 6 Cytogenetic and molecular genetic investigation 10 Genomic investigation 11 The genomic basis of leukaemia 17 Therapeutic approaches 20 Conclusion 25 Bibliography 26 Page 2 2 Abbreviations ALL Acute lymphoblastic leukaemia AML Acute myelogenous leukaemia BAC Bacterial artificial chromosome CD Cluster of differentiation cDNA Complementary DNA CGH Comparative genomic hybridisation CLL Chronic lymphocytic leukaemia CML Chronic myelogenous leukaemia ESP End-sequencing profiling EST Expressed sequence tag FAB French-American-British ...

191 HISTORY OF LEUKAEMIA Highlights in the history of leukaemia - a historical review from the beginnings to current therapeutic developments Xavier Thomas Leukaemia Unit, Haematology Department, Edouard Herriot Hospital, Lyon, France Key words: history ? leukemia ? chemotherapy ? hematopoietic stem cell transplantation * Correspondence: Xavier Thomas, MD, PhD, Service d?Hématologie Clinique, Hôpital Edouard Herriot, 69437 Lyon cedex 03, France, Tel.:+334.2117395, Fax:+334.72117310, e-mail: xavier.thomas@chu-lyon.fr Copyright © Hellenic Society of Haematology HAEMA (Áßìá) ÉSSN: 1108-2682 www.mednet.gr/eae/haema Haema 2006; 9(2): 191-211 Historical review Received: September 27, 2005; Accepted: October 5, 2005 INTRODUCTION While the modern era of leukaemia chemotherapy began recently, the origins of leukaemia treatment have been ...

family wellness 28 ezyhealth&beauty S oh Hooi Peng, 29, and Dave Eng, 44, were both strangers to each other 10 years ago. However, one fateful day in August 1995, their lives intertwined, with one giving hope to the other. Dave had been diagnosed with leukaemia and his only hope was to have a bone marrow transplant, from which he could once again produce his own healthy blood cells. His battle had gone beyond conventional chemotherapy and radiation treatments; he had to find a match quickly. And he did, in Hooi Peng. erfect “When I was 18 and still studying in Raffles JC in 1994, the Bone Marrow Donor Programme (BMDP) representatives came down to the school to do a recruitment talk. Prior to that, I had already known of bone marrow donation through news and stuff I read, though not in detail. Gerald ...